Diagnostic pathology of lymphoproliterative disorders

Pathology

Volumn 37, Issue 6, 2005, Pages 434-456

  Ellis, David W ^a,b   Eaton, Michael ^b   Fox, Richard M ^c   Juneja, Surender ^c   Leong, Anthony S Y ^d   Miliauskas, John ^a   Norris, Debra L ^e   Spagnolo, Dominic ^f   Turner, Jenny ^g  

^a GRIBBLES PATHOLOGY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e QML Pathology   (Australia)

^f PATHWEST LABORATORY MEDICINE   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

Author keywords

Biopsy; Diagnosis; Hodgkin lymphoma; Humans; Immunohistochemistry; Immunology; Lymph nodes; Lymphoma; Pathology; Test performance

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CD30 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR; KI 67 ANTIGEN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN P53; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

ASPIRATION BIOPSY; B CELL LYMPHOMA; BIOPSY TECHNIQUE; CLINICAL FEATURE; DISEASE CLASSIFICATION; DNA MICROARRAY; ENDOSCOPIC BIOPSY; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL CLASSIFICATION OF DISEASES; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOCYTOMA; LYMPHOID HYPERPLASIA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MORPHOLOGY; NEEDLE BIOPSY; PATHOLOGIST; PROGNOSIS; REVIEW; STOMACH LYMPHOMA; WORLD HEALTH ORGANIZATION; CLASSIFICATION; DECISION TREE; FEMALE; LYMPH NODE; MALE; METHODOLOGY; PATHOLOGY;

DECISION TREES; FEMALE; HUMANS; LYMPH NODES; LYMPHOPROLIFERATIVE DISORDERS; MALE; PATHOLOGY, CLINICAL; WORLD HEALTH ORGANIZATION;

EID: 29744461408     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500370309     Document Type: Article

References (149)

1. Jaffe E, Harris N, Stein H, et al. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
2. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Hematol J 2000; 1: 53-66.
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193-207.
4. Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification - from controversy to consensus: the REAL and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11(Suppl 1): 3-10.
5. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
6. Chan WC, Armitage JO, Gascoyne R, et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin lymphoma. Blood 1997; 89: 3909-18.
7. Shipp MA. Can we improve upon the International Index? Ann Oncol 1997; 8: 43-7.
8. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.
9. Melnyk A, Rodriguez A, Pugh WC, et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin lymphoma. Blood 1997; 89: 4514-20.
10. Isobe K, Tamaru J, Harigaya K, et al. Clinicopathological evaluation of the Revised European-American Classification of Lymphoid Neoplasms (REAL) in Japan. Leuk Lymphoma 1999; 34: 143-9.
11. Siebert JD, Harvey LA, Fishkin PA, et al. Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. Am J Clin Pathol 2001; 115: 650-5.
12. Spagnolo DV, Eaton M, Ellis DW, et al. Classification. Draft Clinical Practice Guidelines for the Diagnosis and Management of Lymphoma. Sydney: Australian Cancer Network, 2004. http://www.cancer.org.au/content.cfm?randid= 408243 (accessed September 2005).
13. Rudiger T, Ott G, Ott MM, et al. Differential diagnosis between classic Hodgkin lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998; 22: 1184-91.
14. Jaffe E, Muller-Hermelink HK. Relationshiop Between Hodgkin Disease and and Non-Hodgkin Lymphomas. Philadelphia: Lippincott Raven, 1999.
15. Elgin J, Phillips JG, Reddy VV, et al. Hodgkin and non-Hodgkin lymphoma: spectrum of morphologic and immunophenotypic over lap. Ann Diagn Pathol 1999; 3: 263-75.
16. Kim H. Composite lymphoma and related disorders. Am J Clin Pathol 1993; 99: 445-51.
17. Brauninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin disease and non-Hodgkin lymphoma. N Engl J Med 1999; 340: 1239-47.
18. Fend F, Quintanilla-Martinez L, Kumar S, et al. Composite low grade B-cell lymphomas with two immunophenotypically distinct cell populations are true biclonal lymphomas. A molecular analysis using laser capture microdissection. Am J Pathol 1999; 154: 1857-66.
19. Kuppers R, Sousa AB, Baur AS, et al. Common germinal-center B-cell origin of the malignant cells in two composite lymphomas, involving classical Hodgkin disease and either follicular lymphoma or B-CLL. Mol Med 2001; 7: 285-92.
20. Delabie J, Greiner TC, Chan WC, et al. Concurrent lymphocyte predominance Hodgkin disease and T-cell lymphoma. A report of three cases. Am J Surg Pathol 1996; 20: 355-62.
21. Jaffe ES, Zarate-Osorno A, Kingma DW, et al. The interrelationship between Hodgkin disease and non-Hodgkin lymphomas. Ann Oncol 1994; 5(Suppl 1): 7-11.
22. Abruzzo LV, Griffith LM, Nandedkar M, et al. Histologically discordant lymphomas with B-cell and T-cell components. Am J Clin Pathol 1997; 108: 316-23.
23. Damotte D, Le Tourneau A, Audouin J, et al. Discordant malignant lymphoma synchronous or successive high-grade B lymphoma associated with Hodgkin disease. A clinico pathologic and immunophenotypic study of 4 cases. Pathol Res Pract 1995; 191: 8-15.
24. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
25. Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. European Organization for Research and Treatment of Cancer. Am J Dermatopathol 1999; 21: 265-73.
26. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
27. Jaffe ES, Banks PM, Nathwani B, et al. Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. Mod Pathol 2004; 17: 131-5.
28. Jaffe ES, Banks PM, Nathwani B, et al. Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. The Ad Hoc Committee on reporting of lymphoid neoplasms. Hum Pathol 2002; 33: 1064-8.
29. Compton CC, Harris NL, Ross DW. Protocol for the examination of specimens from patients with non-Hodgkin lymphoma: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999; 123: 68-74.
30. Cousar JB. Surgical pathology examination of lymph nodes. Practice survey by American Society of Clinical Pathologists. Am J Clin Pathol 1995; 104: 126-32.
31. Turner J, Miliauskas J, Eaton M, et al. Biopsy techniques and tissue handling. Draft Clinical Practice Guidelines for the Diagnosis and Management of Lymphoma. Sydney: Australian Cancer Network, 2004. http://www.cancer.org.au/ content.cfm?randid=408243 (accessed September 2005).
32. Levitt S, Cheng L, DuPuis MH, et al. Fine needle aspiration diagnosis of malignant lymphoma with confirmation by immunoperoxidase staining. Acta Cytol 1985; 29: 895-902.
33. Hanson CA. Fine-needle aspiration and immunophenotyping. A role in diagnostic hematopathology? Am J Clin Pathol 1994; 101: 555-6.
34. Liu K, Stern RC, Rogers RT, et al. Diagnosis of hematopoietic processes by fine-needle aspiration in conjunction with flow cytometry: A review of 127 cases. Diagn Cytopathol 2001; 24: 1-10.
35. Weiss LM, Pitts WC. The role of fine needle aspiration biopsy in the diagnosis and management of hemopoietic neoplasms. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
36. Miliauskas J, Turner J, Eaton M, et al. Biopsy techniques and tissue handling. Draft Clinical Practice Guidelines for the Diagnosis and Management of Lymphoma. Sydney: Australian Cancer Network, 2004. http://www.cancer.org.au/ content.cfm?randid=408243 (accessed September 2005).
37. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin lymphoma. Ann Oncol 2001; 12: 1209-10.
38. Park IA, Kim CW. FNAC of malignant lymphoma in an area with a high incidence of T-cell lymphoma. Correlation of accuracy of cytologic diagnosis with histologic subtype and immunophenotype. Acta Cytol 1999; 43: 1059-69.
39. Steel BL, Schwartz MR, Ramzy I. Fine needle aspiration biopsy in the diagnosis of lymphadenopathy in 1103 patients. Role, limitations and analysis of diagnostic pitfalls. Acta Cytol 1995; 39: 76-81.
40. Ravinsky E, Morales C, Kutryk E, et al. Cytodiagnosis of lymphoid proliferations by fine needle aspiration biopsy. Adjunctive value of flow cytometry. Acta Cytol 1999; 43: 1070-8.
41. Chhieng DC, Cohen JM, Cangiarella JF. Cytology and immunophenotyping of low- and intermediate-grade B-cell non-Hodgkin lymphomas with a predominant small-cell component: a study of 56 cases. Diagn Cytopathol 2001; 24: 90-7.
42. Dong HY, Harris NL, Preffer FI, et al. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol 2001; 14: 472-81.
43. Young NA, Al-Saleem TI, Ehya H, et al. Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma. Cancer 1998; 84: 252-61.
44. Nicol TL, Silberman M, Rosenthal DL, et al. The accuracy of combined cytopathologic and flow cytometric analysis of fine-needle aspirates of lymph nodes. Am J Clin Pathol 2000; 114: 18-28.
45. Liu K, Mann KP, Vitellas KM, et al. Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intraabdominal lymphomas. Diagn Cytopathol 1999; 21: 98-104.
46. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90: 2863-92.
47. Meda BA, Buss DH, Woodruff RD, et al. Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol 2000; 113: 688-99.
48. Wakely PE Jr. Fine-needle aspiration cytopathology in diagnosis and classification of malignant lymphoma: accurate and reliable? Diagn Cytopathol 2000; 22: 120-5.
49. Young NA, Al-Saleem T. Diagnosis of lymphoma by fine-needle aspiration cytology using the revised European-American classification of lymphoid neoplasms. Cancer 1999; 87: 325-45.
50. Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1983; 1: 187-92.
51. Sandhaus LM. Fine-needle aspiration cytology in the diagnosis of lymphoma. The next step. Am J Clin Pathol 2000; 113: 623-7.
52. Hehn ST, Grogan TM, Miller TP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 2004; 22: 3046-52.
53. Willman JH, White K, Coffin CM. Pediatric core needle biopsy: strengths and limitations in evaluation of masses. Pediatr Dev Pathol 2001; 4: 46-52.
54. Welch TJ, Sheedy PF 2nd, Johnson CD, et al. CT-guided biopsy: prospective analysis of 1,000 procedures. Radiology 1989; 171: 493-6.
55. Sklair-Levy M, Polliack A, Shaham D, et al. CT-guided core-needle biopsy in the diagnosis of mediastinal lymphoma. Eur Radiol 2000; 10: 714-8.
56. Pappa VI, Hussain HK, Reznek RH, et al. Role of image-guided core-needle biopsy in the management of patients with lymphoma. J Clin Oncol 1996; 14: 2427-30.
57. Silverman SG, Lee BY, Mueller PR, et al. Impact of positive findings at image-guided biopsy of lymphoma on patient care: evaluation of clinical history, needle size, and pathologic findings on biopsy performance. Radiology 1994; 190: 759-64.
58. Ben-Yehuda D, Polliack A, Okon E, et al. Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable. J Clin Oncol 1996; 14: 2431-4.
59. de Kerviler E, Guermazi A, Zagdanski AM, et al. Image-guided core-needle biopsy in patients with suspected or recurrent lymphomas. Cancer 2000; 89: 647-52.
60. Screaton NJ, Berman LH, Grant JW. Head and neck lymphadenopathy: evaluation with US-guided cutting-needle biopsy. Radiology 2002; 224: 75-81.
61. Almasri NM, Zaer FS, Iturraspe JA, et al. Contribution of flow cytometry to the diagnosis of gastric lymphomas in endoscopic biopsy specimens. Mod Pathol 1997; 10: 650-6.
62. Almarsi NM, Zaer FS, Iturraspe JA, Braylan RC. Contribution of flow cytometry to the diagnosis of gastric lymphomas in endoscopic biopsy specimens. Mod Pathol 1997; 10: 650-6; comment 1265-6.
63. Gascoyne RD. Establishing the diagnosis of lymphoma: from initial biopsy to clinical staging. Oncology (Williston Park) 1998; 12: 11-6.
64. Storm FK, Mahvi DM, Hafez GR. Retroperitoneal masses, adenopathy, and adrenal glands. Surg Oncol Clin North Am 1995; 4: 175-84.
65. Lefor AT. Laparoscopic interventions in lymphoma management. Semin Laparosc Surg 2000; 7: 129-39.
66. Mann GB, Conlon KC, LaQuaglia M, et al. Emerging role of laparoscopy in the diagnosis of lymphoma. J Clin Oncol 1998; 16: 1909-15.
67. Gossot D, de Kerviler E, Brice P, et al. Surgical endoscopic techniques in the diagnosis and follow-up of patients with lymphoma. Br J Surg 1998; 85: 1107-10.
68. Warnke R, Isaacson PG. Immunohistochemical analysis of lymphoid tissue. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
69. Knowles DM, Murray A, Chadburn A. Organization and operation of a hematopathology laboratory. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
70. Banks PM. Technical factors in the preparation and evaluation of lymph node biopsies. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
71. Cousar JB, Casey TT, Macon WR, et al. Lymph nodes. In: Sternberg SS, editor. Diagnostic Surgical Pathology. Philadelphia: Lippincott Williams and Wilkins, 1999.
72. Le Beau MM. Role of cytogenetics in the diagnosis and classification of hemopoietic neoplasms. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
73. Leith CP, Willman C. Flow cytometric analysis of hematologic specimens. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
74. Miliauskas J. Lymph node sampling for flow cytometric analysis. Pathology 2002; 34: 481.
75. Butmarc JR, Kourea HP, Levi E, et al. Improved detection of CD5 epitope in formalin-fixed paraffin-embedded sections of benign and neoplastic lymphoid tissues by using biotinylated tyramine enhancement after antigen retrieval. Am J Clin Pathol 1998; 109: 682-8.
76. Leong AS, Lee ES, Yin H, et al. Superheating antigen retrieval. Appl Immunohistochem Mol Morphol 2002; 10: 263-8.
77. Knowles DM. Immunophenotypic markers useful in the diagnosis and classification of hemopoietic neoplasms. In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams and Wilkins, 2001.
78. Leong AS-Y, Cooper K, Leong FJ. Manual of Diagnostic Antibodies for Immunohistology. London: Greenwich Medical Media, 1999.
79. Spagnolo DV, Ellis DW, Juneja S, et al. The role of molecular studies in lymphoma diagnosis: a review. Pathology 2004; 36: 19-44.
80. Catalano A, Iland H. Molecular biology of lymphoma in the microarray era. Pathology 2005; 37: 508-22.
81. Campbell LJ. Cytogenetics of lymphomas. Pathology 2005; 37: 493-507.
82. Ellis DW. Lymphoproliferative disorders. In: Leong AS-Y, editor. Applied Immunohistochemistry for the Surgical Pathologist. London: Edward Arnold, 1993; 109-207.
83. Ellis DW, Eaton M, Fox RM, et al. Diagnosis and reporting of lymphoproliferative disease. Draft Clinical Practice Guidelines for the Diagnosis and Management of Lymphoma. Sydney: Australian Cancer Network, 2004. http://www.cancer.org.au/content.cfm?randid=408243 (accessed September 2005).
84. Crowley KS. Lymph node biopsy. Pathology 1983; 15: 137-8.
85. Banks PM, Long JC, Howard CA. Preparations of lymph node biopsy specimens. Hum Pathol 1979; 10: 617-21.
86. Chan JKC. Reactive lymphadenopathies. In: Weiss LM, editor. Pathology of Lymph Nodes. New York: Churchill Livingstone, 1996.
87. Schroer KR, Franssila KO. Atypical hyperplasia of lymph nodes: a follow-up study. Cancer 1979; 44: 1155-63.
88. Sadek I, Greer W, Foyle A. Diagnosis of lymphoproliferative disorders: experience of a single institution in the long-term follow-up of discordant cases. Clin Invest Med 2000; 23: 366-75.
89. Williams ME, Lee JT, Innes DJ, et al. Immunoglobulin gene rearrangement in abnormal lymph node hyperplasia. Am J Clin Pathol 1991; 96: 746-54.
90. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin disease and related diseases ('grey zone' lymphoma). Ann Oncol 1998; 9(Suppl 5): S31-8.
91. Allen PW. Commonwealth Benefits Renumeration. General Forum: Royal College of Pathologists of Australasia. Sydney: Royal College of Pathologists of Australasia, 2001.
92. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-6.
93. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44 (Suppl 3): S41-7.
94. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-69.
95. Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301-7.
96. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-74.
97. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74.
98. Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-72.
99. de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003; 43: 509-28.
100. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
101. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16: 1931-9.
102. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin lymphomas. Blood 1997; 89: 601-9.
103. Moller MB, Gerdes AM, Skjodt K, et al. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin lymphoma. Clin Cancer Res 1999; 5: 1085-91.
104. Osada M, Ishioka C, Ichinohasama R, et al. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin lymphoma. Anticancer Drug Des 1999; 14: 107-14.
105. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131-8.
106. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
107. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin lymphoma. Blood 1997; 90: 244-51.
108. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.
109. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-43.
110. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-73.
111. Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001; 27: 206-16.
112. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-84.
113. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 74-80.
114. Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117: 322-32.
115. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98: 945-51.
116. Braaten KM, Betensky RA, de Leval L, et al. BCL6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063-9.
117. Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-62.
118. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
119. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
120. de Jong D, Glas AM, Boerrigter L, et al. Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood 2003; 102: 324-7.
121. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-5.
122. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-62.
123. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-9.
124. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995; 85: 3671-8.
125. Ghielmini M, Mora O. Does the FLIPI apply to grade 3 follicular lymphoma? Blood 2005; 105: 4892; author reply 4892-3.
126. Ashton-Key M, Diss TC, Isaacson PG, et al. A comparative study of the value of immunohistochemistry and the polymerase chain reaction in the diagnosis of follicular lymphoma. Histopathology 1995; 27: 501-8.
127. Koster A. Intrafollicular proliferation rate is superior to histological grading in predicting outcome in follicular lymphoma. Ann Oncol 2005; 16: A076.
128. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-84.
129. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-75.
130. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-51.
131. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-11.
132. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.
133. Ye H, Liu H, Raderer M, et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101: 2547-50.
134. Liu H, Ye H, Ruskone-Fourmestraux A, et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-94.
135. Starostik P, Patzner J, Greiner A, et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 2002; 99: 3-9.
136. Maes B, Demunter A, Peeters B, et al. BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression. Blood 2002; 99: 1398-404.
137. Chen YW, Wong KY, Au WY, et al. BCL10 somatic mutations rarely occur in gastric lymphoma: detection of high frequency of polymorphisms in BCL10 coding region. Cancer Genet Cytogenet 2001; 127: 184-7.
138. Kuo SH, Chen LT, Yeh KH, et al. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol 2004; 22: 3491-7.
139. Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106: 1037-41.
140. Raty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11-20.
141. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975-81.
142. Walsh SH, Thorselius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003; 101: 4047-54.
143. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-97.
144. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-32.
145. ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43: 462-9.
146. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-21.
147. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000; 96: 2993-3000.
148. Rassidakis GZ, Goy A, Medeiros LJ, et al. Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003; 9: 2213-20.
149. Jacobsen J. Director's challenge: Towards a molecular classification of tumours. Bethesda: National Cancer Institute, 1999. RFA: CA-98-027, http://www.nci.nih.gov/initiatives/director.html (accessed September 2005).